Disposition of 6198 shares by Van Houte Hans of Nurix Therapeutics at 11.3331 subject to Rule 16b-3
| NRIX Stock | USD 11.28 0.24 2.17% |
Slightly above 55% of Nurix Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Nurix Therapeutics stock suggests that some investors are interested at this time. Nurix Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Nurix Therapeutics' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Nurix Therapeutics Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Nurix Therapeutics Fundamental Analysis
We analyze Nurix Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Nurix Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Nurix Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nurix Therapeutics stock to make a market-neutral strategy. Peer analysis of Nurix Therapeutics could also be used in its relative valuation, which is a method of valuing Nurix Therapeutics by comparing valuation metrics with similar companies.
Peers
Nurix Therapeutics Related Equities
| IPSC | Century Therapeutics | 5.66 | ||||
| RVMD | Revolution Medicines | 3.25 | ||||
| FHTX | Foghorn Therapeutics | 3.01 | ||||
| ITOS | Iteos Therapeutics | 0.1 | ||||
| CCCC | C4 Therapeutics | 0.94 | ||||
| KYMR | Kymera Therapeutics | 1.58 | ||||
| RLAY | Relay Therapeutics | 3.29 |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.